Toluene → 2-Benzyloxycarbonylamino-3-{2-methoxy-5-methyl-6-[4-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-piperidin-1-yl]-pyrimidin-4-ylamino}-propionic acid bis (trifluoroacetate)
反応式
[CH2:1]([O:8][C:9]([NH:11][CH:12]([CH2:20][NH:21][C:22]1[C:27]([CH3:28])=[C:26]([N:29]2[CH2:34][CH2:33][CH:32]([C:35]3[CH:44]=[CH:43][C:42]4[CH2:41][CH2:40][CH2:39][NH:38][C:37]=4[N:36]=3)[CH2:31][CH2:30]2)[N:25]=[C:24]([O:45][CH3:46])[N:23]=1)[C:13]([O:15]C(C)(C)C)=[O:14])=[O:10])[C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][CH:3]=1.[F:47][C:48]([F:53])([F:52])[C:49]([OH:51])=[O:50].ClCCl.CO.O.C(O)(=O)C.C1(C)C=CC=CC=1>ClCCl>[F:47][C:48]([F:53])([F:52])[C:49]([OH:51])=[O:50].[F:47][C:48]([F:53])([F:52])[C:49]([OH:51])=[O:50].[CH2:1]([O:8][C:9]([NH:11][CH:12]([CH2:20][NH:21][C:22]1[C:27]([CH3:28])=[C:26]([N:29]2[CH2:34][CH2:33][CH:32]([C:35]3[CH:44]=[CH:43][C:42]4[CH2:41][CH2:40][CH2:39][NH:38][C:37]=4[N:36]=3)[CH2:31][CH2:30]2)[N:25]=[C:24]([O:45][CH3:46])[N:23]=1)[C:13]([OH:15])=[O:14])=[O:10])[C:2]1[CH:3]=[CH:4][CH:5]=[CH:6][CH:7]=1参加物
6
反応物 4
生成物 1
試薬・触媒・溶媒 1
実験手順
200 mg (0.317 mmole) of tert-butyl 2-benzyloxycarbonylamino-3-{2-methoxy-5-methyl-6-[4-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-piperidin-1-yl)-pyrimidin-4-ylamino}-propionate in 10 ml of dichloromethane with 2 ml of trifluoroacetic acid is stirred at ambient temperature until the starting product disappears according to TLC (silica gel, eluent: CH2Cl2-MeOH—H2O—AcOH 90-10-1-1). Toluene is added and the reaction mixture is evaporated to dryness under reduced pressure (2 kPa). The residue is solubilized in the minimum amount of dichloromethane then poured into diisopropyl ether. 170 mg of expected product is obtained in the form of a beige solid.
後処理
- customthe reaction mixture is evaporated to dryness under reduced pressure (2 kPa)
- additionthen poured into diisopropyl ether
出典と根拠
- ORDレコード
- ord-3d833b2cbb214b4a9091ac742d1063ae
- 出典データセット
- uspto-grants-2012_03
- 特許番号
- US08133896B2
反応ノート
読み込み中…